113. Muscular dystrophy Clinical trials / Disease details
Clinical trials : 622 / Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04254172 (ClinicalTrials.gov) | February 19, 2020 | 31/1/2020 | A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy | A SINGLE-SITE, PROSPECTIVE, NATURAL HISTORY LOW INTERVENTIONAL STUDY TO ESTABLISH NORMATIVE DATA OF REAL-WORLD ACTIVITY MEASURES USING WEARABLE SENSORS IN AMBULATORY BOYS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) | Duchenne Muscular Dystrophy (DMD) | Device: Activity Monitor | Pfizer | NULL | Terminated | 4 Years | 12 Years | Male | 2 | United States | |
2 | NCT04999735 (ClinicalTrials.gov) | April 14, 2019 | 2/7/2019 | Digital Biotyping of FSHD Patients and Controls | An Exploratory, Non-interventional Study to Biotype Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Controls Using Digital Technologies | Muscular Dystrophy, Facioscapulohumeral | Behavioral: CHDR Monitoring Remotely (MORE);Behavioral: Withings Steel HR;Behavioral: Withings Body+ scale;Behavioral: Withings Blood Pressure Monitor | Centre for Human Drug Research, Netherlands | Facio Therapeutics | Completed | 16 Years | N/A | All | 58 | Netherlands |